vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $359.9M, roughly 1.7× AdvanSix Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -0.8%, a 41.6% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $36.1M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
ASIX vs EXEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $598.7M |
| Net Profit | $-2.8M | $244.5M |
| Gross Margin | 7.6% | 95.6% |
| Operating Margin | -0.7% | 39.3% |
| Net Margin | -0.8% | 40.8% |
| Revenue YoY | 9.4% | 5.6% |
| Net Profit YoY | -892.9% | 74.8% |
| EPS (diluted) | $-0.11 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | $359.9M | $597.8M | ||
| Q3 25 | $374.5M | $568.3M | ||
| Q2 25 | $410.0M | $555.4M | ||
| Q1 25 | $377.8M | $566.8M | ||
| Q4 24 | $329.1M | — | ||
| Q3 24 | $398.2M | $539.5M | ||
| Q2 24 | $453.5M | $637.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | $-2.8M | $193.6M | ||
| Q3 25 | $-2.6M | $184.8M | ||
| Q2 25 | $31.4M | $159.6M | ||
| Q1 25 | $23.3M | $139.9M | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $118.0M | ||
| Q2 24 | $38.9M | $226.1M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | 7.6% | 96.9% | ||
| Q3 25 | 6.8% | 96.6% | ||
| Q2 25 | 14.3% | 96.5% | ||
| Q1 25 | 14.2% | 96.5% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | 96.8% | ||
| Q2 24 | 17.9% | 97.2% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | -0.7% | 39.6% | ||
| Q3 25 | -0.9% | 37.6% | ||
| Q2 25 | 7.7% | 33.6% | ||
| Q1 25 | 7.7% | 28.8% | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | 7.5% | 25.2% | ||
| Q2 24 | 11.5% | 43.3% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | -0.8% | 32.4% | ||
| Q3 25 | -0.7% | 32.5% | ||
| Q2 25 | 7.7% | 28.7% | ||
| Q1 25 | 6.2% | 24.7% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | 21.9% | ||
| Q2 24 | 8.6% | 35.5% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-0.11 | $0.69 | ||
| Q3 25 | $-0.10 | $0.65 | ||
| Q2 25 | $1.15 | $0.55 | ||
| Q1 25 | $0.86 | $0.47 | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.82 | $0.40 | ||
| Q2 24 | $1.43 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $2.2B |
| Total Assets | $1.7B | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $19.8M | $988.5M | ||
| Q3 25 | $23.7M | $791.1M | ||
| Q2 25 | $18.4M | $1.0B | ||
| Q1 25 | $8.3M | $1.1B | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $17.3M | $1.2B | ||
| Q2 24 | $12.1M | $1.0B |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $815.2M | $2.2B | ||
| Q3 25 | $818.2M | $2.0B | ||
| Q2 25 | $823.7M | $2.1B | ||
| Q1 25 | $794.4M | $2.2B | ||
| Q4 24 | $774.6M | — | ||
| Q3 24 | $766.4M | $2.3B | ||
| Q2 24 | $746.6M | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $1.7B | $2.8B | ||
| Q3 25 | $1.7B | $2.7B | ||
| Q2 25 | $1.6B | $2.8B | ||
| Q1 25 | $1.6B | $2.9B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $3.0B | ||
| Q2 24 | $1.5B | $2.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $333.5M |
| Free Cash FlowOCF − Capex | $36.1M | $332.4M |
| FCF MarginFCF / Revenue | 10.0% | 55.5% |
| Capex IntensityCapex / Revenue | 7.7% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $63.7M | $290.3M | ||
| Q3 25 | $26.6M | $49.0M | ||
| Q2 25 | $21.1M | $211.4M | ||
| Q1 25 | $11.4M | $240.3M | ||
| Q4 24 | $64.2M | — | ||
| Q3 24 | $57.3M | $271.3M | ||
| Q2 24 | $50.2M | $119.5M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | $36.1M | $288.8M | ||
| Q3 25 | $66.0K | $46.2M | ||
| Q2 25 | $-7.2M | $208.5M | ||
| Q1 25 | $-22.6M | $236.3M | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | $263.1M | ||
| Q2 24 | $16.7M | $113.0M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | 10.0% | 48.3% | ||
| Q3 25 | 0.0% | 8.1% | ||
| Q2 25 | -1.7% | 37.5% | ||
| Q1 25 | -6.0% | 41.7% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | 48.8% | ||
| Q2 24 | 3.7% | 17.7% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | 7.7% | 0.2% | ||
| Q3 25 | 7.1% | 0.5% | ||
| Q2 25 | 6.9% | 0.5% | ||
| Q1 25 | 9.0% | 0.7% | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | 1.5% | ||
| Q2 24 | 7.4% | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | 0.67× | 1.32× | ||
| Q1 25 | 0.49× | 1.72× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | 2.30× | ||
| Q2 24 | 1.29× | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
